154 related articles for article (PubMed ID: 15598772)
1. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Berchuck A; Schildkraut JM; Wenham RM; Calingaert B; Ali S; Henriott A; Halabi S; Rodriguez GC; Gertig D; Purdie DM; Kelemen L; Spurdle AB; Marks J; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2141-7. PubMed ID: 15598772
[TBL] [Abstract][Full Text] [Related]
2. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors.
Nagle CM; Olsen CM; Webb PM; Jordan SJ; Whiteman DC; Green AC; ;
Eur J Cancer; 2008 Nov; 44(16):2477-84. PubMed ID: 18707869
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
4. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
Pearce CL; Hirschhorn JN; Wu AH; Burtt NP; Stram DO; Young S; Kolonel LN; Henderson BE; Altshuler D; Pike MC
J Natl Cancer Inst; 2005 Jan; 97(1):51-9. PubMed ID: 15632380
[TBL] [Abstract][Full Text] [Related]
5. PGR +331 A/G and increased risk of epithelial ovarian cancer.
Risch HA; Bale AE; Beck PA; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1738-41. PubMed ID: 16985038
[TBL] [Abstract][Full Text] [Related]
6. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer.
Romano A; Lindsey PJ; Fischer DC; Delvoux B; Paulussen AD; Janssen RG; Kieback DG
Gynecol Oncol; 2006 May; 101(2):287-95. PubMed ID: 16360811
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer.
Leite DB; Junqueira MG; de Carvalho CV; Massad-Costa AM; Gonçalves WJ; Nicolau SM; Lopes LA; Baracat EC; da Silva ID
Steroids; 2008 Jul; 73(6):676-80. PubMed ID: 18384825
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and risk of epithelial ovarian cancer.
Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
[TBL] [Abstract][Full Text] [Related]
9. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers.
Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A
Cancer Detect Prev; 2007; 31(2):102-9. PubMed ID: 17418979
[TBL] [Abstract][Full Text] [Related]
10. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk.
De Vivo I; Hankinson SE; Colditz GA; Hunter DJ
Cancer Res; 2003 Sep; 63(17):5236-8. PubMed ID: 14500352
[TBL] [Abstract][Full Text] [Related]
11. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Spurdle AB; Hopper JL; Chen X; Dite GS; McCredie MR; Giles GG; Venter DJ; Southey MC; Purdie DM; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1287-93. PubMed ID: 11751447
[TBL] [Abstract][Full Text] [Related]
12. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
Spurdle AB; Hopper JL; Chen X; McCredie MR; Giles GG; Venter DJ; Southey MC; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):439-43. PubMed ID: 12010857
[TBL] [Abstract][Full Text] [Related]
13. GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/A polymorphism.
Huggins GS; Wong JY; Hankinson SE; De Vivo I
Cancer Res; 2006 Feb; 66(3):1384-90. PubMed ID: 16452193
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk.
Lurie G; Wilkens LR; Thompson PJ; McDuffie KE; Carney ME; Terada KY; Goodman MT
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2566-71. PubMed ID: 18086759
[TBL] [Abstract][Full Text] [Related]
15. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
Modugno F; Ness RB; Allen GO; Schildkraut JM; Davis FG; Goodman MT
Am J Obstet Gynecol; 2004 Sep; 191(3):733-40. PubMed ID: 15467532
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies.
Johnatty SE; Spurdle AB; Beesley J; Chen X; Hopper JL; Duffy DL; Chenevix-Trench G;
Breast Cancer Res Treat; 2008 May; 109(1):91-9. PubMed ID: 17592773
[TBL] [Abstract][Full Text] [Related]
17. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome.
Ludwig AH; Murawska M; Panek G; Timorek A; Kupryjanczyk J
Endocr Relat Cancer; 2009 Sep; 16(3):1005-16. PubMed ID: 19458022
[TBL] [Abstract][Full Text] [Related]
18. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer.
Webb PM; Hopper JL; Newman B; Chen X; Kelemen L; Giles GG; Southey MC; Chenevix-Trench G; Spurdle AB
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):319-23. PubMed ID: 15734952
[TBL] [Abstract][Full Text] [Related]
19. Association of endometrial cancer risk with a functional polymorphism (Asp(327)Asn) in the sex hormone-binding globulin gene.
Kataoka N; Cai Q; Xu WH; Xiang YB; Cai H; Zheng W; Shu XO
Cancer; 2007 Apr; 109(7):1296-302. PubMed ID: 17315164
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 polymorphism and the risk of endometrial cancer.
Kang S; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2005 May; 97(2):431-5. PubMed ID: 15863141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
